Upload Avatar (500 x 500)
Bing Chen
Medical School
Nanjing University
Jiangsu
Language: Chinese, English
Multiple Myeloma
Clinical Research
Basic Research
Hematology
Immunotherapy
Malignant Diseases
Biological Therapy
Stem Cell Transplantation
Leukemia
Targeted Therapy
Areas of Focus
- Basic and clinical research of multiple myeloma
- Biological immunotherapy research of malignant hematological diseases
Work Experience
- 1995 - Present - Nanjing Drum Tower Hospital - Clinical work in hematology
- 2012 - Visiting Scholar at Memorial Sloan Kettering Cancer Center
Academic Background & Achievements
- 1995 - Nanjing Drum Tower Hospital - Clinical work in hematology
- 2012 - Visiting Scholar at Memorial Sloan Kettering Cancer Center
Publications
- Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma, Bing Chen, 2021
- Bortezomib activation of mTORC1C1 pathway mediated by NOX2-drived reactive oxygen species results in apoptosis in primary dorsal root ganglion neurons, Bing Chen, 2021
- Nomogram for Predicting the Overall Survival of Adult Patients With Primary Gastrointestinal Diffuse Large B Cell Lymphoma: A SEERBased Study, Bing Chen, 2020
- Abnormal PTBP1 Expression Sustains the Disease Progression of Multiple Myeloma, Bing Chen, 2020
- MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation, Bing Chen, 2020
- Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment, Bing Chen, 2020
- Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation A Systematic Review and Network Meta-analysis, Bing Chen, 2020
- BAG3 regulates multiple myeloma cell proliferation through FOXM1/Rb/E2F axis, Bing Chen, 2020
- Vincristine-loaded platelets coated with anti-CD41 mAbs: a new macrophage targeting proposal for the treatment of immune thrombocytopenia, Bing Chen, 2019
- Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma, Bing Chen, 2019
- TREM1/Dap12-based CAR-T cells show potent antitumor activity, Bing Chen, 2019
- Prognostic Value of 1q21 Gain in Multiple Myeloma, Bing Chen, 2019
- Development of follicular lymphoma after treatment of diffuse large B-cell lymphoma: two case reports with review of literature, Bing Chen, 2018
- Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma, Bing Chen, 2018
- Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment, Bing Chen, 2018
- Acute lymphoblastic leukemia in a patient with IgG4-related disease, Bing Chen, 2018
- Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment, Bing Chen, 2017
- Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors, Bing Chen, 2017
- The association between expression of hypoxia inducible factor1α and multi-drug resistance of acute myeloid leukemia, Bing Chen, 2017
- The polymorphism of JAK2 rs56118985 may be a predictive marker of the treatment responses of acute myeloid leukemia patients, Bing Chen, 2017
- Expression of MAGEC1/CT7 provides prognostic information in multiple myeloma, Bing Chen, 2017
Awards
- 2020 - Jiangsu Province Medical New Technology Introduction Award, First Prize
- 2017 - Nanjing Science and Technology Progress Award, Third Prize
- 2017 - Jiangsu Province Medical New Technology Introduction Award, Second Prize
- 2017 - Jiangsu Oncology Medical Science and Technology Award, Second Prize
- 2013 - Jiangsu Province Medical New Technology Introduction Award, First Prize
- 2012 - Jiangsu Province Science and Technology Progress Award, Third Prize
- 2011 - Nanjing Science and Technology Progress Award, Third Prize
